Abstract:Mycoplasmas are host-restricted prokaryotes with a nearly minimal genome. To overcome their metabolic limitations, these wall-less bacteria establish intimate interactions with epithelial cells at mucosal surfaces. The alarming rate of antimicrobial resistance among pathogenic species is of particular concern in the medical and veterinary fields. Taking advantage of the reduced mycoplasma genome, random transposon mutagenesis was combined with high-throughput screening in order to identify key determinants of mycoplasma survival in the host-cell environment and potential targets for drug development. With the use of the ruminant pathogen Mycoplasma bovis as a model, three phosphodiesterases of the DHH superfamily were identified as essential for the proliferation of this species under cell culture conditions, while dispensable for axenic growth. Despite a similar domain architecture, recombinant Mbov_0327 and Mbov_0328 products displayed different substrate specificities. While rMbovP328 protein exhibited activity towards cyclic dinucleotides and nanoRNAs, rMbovP327 protein was only able to degrade nanoRNAs. The Mbov_0276 product was identified as a member of the membrane-associated GdpP family of phosphodiesterases that was found to participate in cyclic dinucleotide and nanoRNA degradation, an activity which might therefore be redundant in the genome-reduced M. bovis. Remarkably, all these enzymes were able to convert their substrates into mononucleotides, and medium supplementation with nucleoside monophosphates or nucleosides fully restored the capacity of a Mbov_0328/0327 knock-out mutant to grow under cell culture conditions. Since mycoplasmas are unable to synthesize DNA/RNA precursors de novo, cyclic dinucleotide and nanoRNA degradation are likely contributing to the survival of M. bovis by securing the recycling of purines and pyrimidines. These results point toward proteins of the DHH superfamily as promising targets for the development of new antimicrobials against multidrug-resistant pathogenic mycoplasma species.

Application of Protein Expression in Mycoplasma Study

Genomic Variability and Post-translational Protein Processing Enhance the Immune Evasion of Mycoplasma Hyopneumoniae and Its Interaction with the Porcine Immune System

The Fate of Cell Infected With Mycoplasma

Mycoplasmas As Host Pantropic and Specific Pathogens: Clinical Implications, Gene Transfer, Virulence Factors, and Future Perspectives

Progress on Secretory Proteins of Mycoplasma

Infection strategies of mycoplasmas: Unraveling the panoply of virulence factors

Gene Editing Tools for Mycoplasmas: References and Future Directions for Efficient Genome Manipulation

Development of a Replicative Plasmid for Gene Expression in Mycoplasma Bovis.

Mycoplasma invasion into host cells: An integrated model of infection strategy

Expression of recombinant protein using Corynebacterium Glutamicum: progress, challenges and applications

Proteomic Study of Mycoplasma Suis Using the Gel-Based Shotgun Strategy

Application of Proteomics in the Study of Mycobacterium tuberculosis

Application and research progress of MultiBac: A review

Mycoplasma bovis MbovP579 protein and application thereof

Comparative Genomics Of Mycoplasma: Analysis Of Conserved Essential Genes And Diversity Of The Pan-Genome

Synthesis, cloning, and expression of Mycoplasma suis inorganic pyrophosphatase gene using PCR-based accurate synthesis and overlap-extension PCR, and its immunogenicity analysis.

Prokaryotic Expression of Mycoplasma Hyopneumoniae LppB and Its Biological Characteristics

Progress on Membrane Proteins of Mycoplasma bovis

Rescue of mutant fitness defects using in vitro reconstituted designer transposons in Mycoplasma mycoides

Synthesizing and Prokaryotic Expression of Mycoplasma Haemosuis ORF9 Gene

An Emerging Role for Cyclic Dinucleotide Phosphodiesterase and Nanornase Activities in Mycoplasma Bovis: Securing Survival in Cell Culture